Nearly all Americans nationwide agree: Lowering out-of-pocket costs for health care should be a top priority for policymakers. Luckily, there are commonsense policies Congress could implement to meaningfully address the cost burdens Americans face. These include things like making sure patients aren’t paying more for their medicines than their health insurance company or requiring first-dollar coverage, so insurance companies cover the cost of certain lifesaving medicines from day one of the plan year. These are concrete steps, but they aren’t the only ones Congress could take.
Take 340B. It would be a mistake if Congress continued to overlook the critically important need to fix the 340B Drug Pricing Program to ensure it is making medicines more affordable for low-income and other vulnerable patients.
Here's how the program is (not) working.
Biopharmaceutical manufacturers provide steep discounts on outpatient medications (amounting to tens of billions of dollars a year) to 340B covered entities, which include certain hospitals and community health centers. These savings are supposed to be used by 340B covered entities to ensure patients have affordable access to medicines. Instead, large hospitals can buy deeply discounted 340B medicines and then turn around and charge patients higher prices, often using profits to buy community-based physician practices in wealthier neighborhoods to generate even more revenue from the 340B program. Check out recent coverage from the New York Times and the Wall Street Journal on ways hospitals are abusing the program.
Here’s how 340B is hurting patients.
A lack of oversight and transparency has allowed these abuses to continue, resulting in reduced access to affordable care, greater health inequities and higher health care costs nationwide. Some key facts to keep in mind:
- 340B hospitals are gobbling up competitors in a way that consolidates health care providers and reduces access to needed care. A new analysis from Avalere looked at the characteristics of hospitals that underwent a merger or acquisition between 2016 and 2022. Compared to both the national average for all short-term acute care hospitals, as well as the average for hospitals that were purchased, buying hospitals were more likely to be larger (have at least 500 beds), not-for-profit and a 340B hospital. This consolidation creates powerful, large hospital systems that raise costs for patients and insurers, creating a financial barrier for patients trying to access medicines.
- The 340B program has devolved from one intended to make health care more equitable to one that drives disparities in how certain populations access care. In fact, a study published in Health Affairs found 340B hospitals were expanding into more affluent areas to generate higher profits, leaving the patients who really need this program behind.
- While hospitals get a discount so steep that some medicines only cost them a penny, they often charge patients inflated prices. Research has shown that 340B hospitals often prescribe more expensive medicines than non-340B hospitals and significantly mark up the price of medicines. These practices have unfortunate implications for what patients pay out of pocket. A Milliman analysis found the cost per outpatient prescription filled at 340B hospitals was, on average, more than 150% higher than the cost of outpatient prescriptions filled at non-340B hospitals.
Here’s how Congress can help.
Currently there are no requirements for patients to benefit from the 340B program, and hospitals can participate even if they engage in aggressive debt collection and provide minimal levels of charity care. For starters, Congress should require hospitals to offer low-income and other vulnerable patients a discount on their medicines. If hospitals get a discount, why shouldn’t low-income and uninsured patients? Congress should also update and strengthen hospital eligibility standards to ensure hospitals participating in the program do in fact support underserved communities.
When taking a holistic look at our health care system and areas that are impacting patient spending, the 340B program cannot be overlooked. It’s time to address the perverse incentives that expose patients to higher out-of-pocket costs and take steps to ensure the program supports low-income and vulnerable patients’ access to affordable medicines. Learn more at PhRMA.org/340B.
Nicole Longo
Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Nicole Longo
New Report: Hospitals, clinics and for-profit partners pocketed $142B in 2025 from 340B
Hospitals are hiding information that could lower costs for patients
As football season kicks off, hospitals keep scoring on 340B
ICYMI: Hospital consolidation is driving up health care costs
It's time to modernize 340B: The case for a rebate model
ICYMI: Fox business hosts call 340B a ‘Rotten System’ and ‘Cash Cow’ for hospitals
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
340B’s lack of guardrails lets big hospital systems turn it into an oversight-free revenue stream
Private equity's new play? Become a nonprofit to profit off 340B.
340B is growing, but it is unclear if Illinois patients benefit
Fox Business spotlights hospitals abuse of the 340B program
The Wall Street Journal raises new alarms about 340B
Hospitals in the hot seat: Congress sharpens focus on 340B, consolidation and rising costs
New "Goldmine” ad reveals hospitals hide how they profit from 340B markups
A program off track: How 340B drives both hospital consolidation and system gaming
Washington Post Editorial Board says 340B has become “corporate welfare”
Modernizing 340B using rapid verification: The case for a rebate model
Hospitals drive nearly 80% of the U.S. health spending gap
Congress should look under the hood of 340B, hospitals don't want them to
340B hospitals buy low and sell high, a new analysis shows
New report from Minnesota: 340B is generating billions for big hospitals
340B hospital markup scheme is costing states, taxpayers billions
Questions mount over 340B program and increased cost to everyone
PhRMA Forum 2026 highlights the importance of fostering the next era of American leadership
50-state poll says Americans are concerned that hospital markups hurt patients
New analysis finds 340B hospitals push patients toward costly care to boost profits
Data shows tax-exempt hospital profit-seeking behavior, not drug prices, is driving explosive 340B expansion
Big, tax-exempt hospitals are charging cancer patients, employers massive medicine markups
340B’s billion-dollar boom: Oversight lags as spending soars
New study: 340B rebate model pilot won’t hurt cash flow for providers
One thing the Senate can agree on: It’s time to fix 340B
Middlemen mark up drug prices and keep discounts meant for you
The Administration approves manufacturers’ 340B rebate pilot plans
340B abuses are fueling higher Medicare costs, new BRG report shows
ICYMI: The Wall Street Journal calls 340B reform a “good idea to cut drug costs”
340B hospitals use scare tactics to evade accountability
Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states
CBO: 340B program costs taxpayers, no evidence patients benefit
PhRMA stresses importance of 340B Rebate Model Pilot
New “Meet Mark” ad exposes how the 340B hospital markup program drives up costs for everyone
New study unmasks how big-city hospitals exploit 340B by posing as rural providers
Study: 340B hospitals drive up patient drug costs
Curbing 340B abuse and rising costs with the rebate model
The hidden cost of 340B: A multi-billion-dollar burden on taxpayers and Medicaid
Latest analysis from Ohio exposes growing abuses of the 340B markup program
New report finds rampant abuse of the 340B program
How the 340B hospital markup program could hurt Michigan patients
New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines
How the 340B hospital markup program and PBMs drive up costs for U.S. patients
Foreign first pricing schemes don’t address why Americans pay more
When hospitals have free rein to mark up drug prices, who pays the price?
New report finds more abuse of 340B program by hospitals and drug middlemen
A closer look at how health care consolidation drives up patient costs, creates barriers to care
340B markup program is a hidden tax, increasing costs for employers, straining state and federal budgets
New report sheds light on payment flows in the pharmaceutical supply chain, including the role of 340B and vertical integration
Wrapping up the J.P. Morgan Healthcare Conference
NYT exposes hospitals, middlemen make millions off a hospital markup program
PhRMA CEOs Tee Up Next Week's Health Care Conference
New study: Entities that don’t make medicines get half of what is spent on those medicines
A new administration poses new opportunities for patient access
New 340B report from Minnesota exposes steep hospital markups on medicines, patient benefits remain unclear
Michigan hospitals using federal program to markup cost of medicines, gouging patients
340B spending is exploding, forcing prices up for patients, employers and government programs
Three things to know about 340B contract pharmacies
PhRMA urges HRSA not to impede new 340B pricing approaches to improve transparency and integrity
Illegal abuse of 340B hurts us all
340B sales go up, free or reduced-cost care offered at hospitals goes down
ICYMI: Health care policy should be driven by patients, not politics
The hidden bill patients don’t know they are paying
340B grows and grows, but patients do not see the savings
340B grows and grows, but patients do not see the savings
PBMs using 340B program to drive profits at patients’ expense
What’s the 340B program like in your state?
New year, same exploitation of the 340B program
How the 340B program became a PBM giveaway
New report adds to questions about nonprofit status of 340B hospitals
By the Numbers: 340B continues to climb in profits, dwindle with patient support
New 340B Mega Guidance
New report: Hospitals mark up medicine prices 500%
read more
PhRMA responds to Senate: Today’s 340B program leaves patients behind | PhRMA
New studies add to body of evidence questioning 340B efficacy
340B program reaches $100 billion in sales, while patients are left behind
Nonprofit hospitals fall short on community benefit, studies show
What they are saying: Nonprofit hospitals are gaming the system at the expense of patients
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
340B program continues to drive shift in care to more expensive hospital settings
The 340B program is interfering with the U.S. biosimilars market and impacting patient costs
Three ways 340B is failing vulnerable patients
If patients aren’t benefiting from the 340B program, who is?
New data: The 340B program is driving up costs for patients and our health care system
Word of the Month: 340B covered entity
340B program remains second largest federal drug program, yet little solid evidence of benefits to patient
Study after study after study: Contract pharmacy expansion not aligned in communities 340B is meant to serve
New research finds gaps in charity care provided by 340B hospitals
New analysis confirms hospitals markup prices for oncology therapies
By the numbers: Contract pharmacy participation in the 340B program
340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients
New study finds more than half of brand medicine spending goes to the supply chain and others
Making medicines more affordable: Preserving safety-net programs like 340B
Fact Check: Do contract pharmacies help patients access 340B medicines? No.
New video: Why changes to the 340B program are essential for patients
To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system
New analysis adds to research questioning whether 340B is working as Congress intended
340B hospitals among those that provide lowest levels of community benefit across the country
Getting the 340B program back on track in 2021
Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients
Fact Check: How hospitals continue to drive health care spending
PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients
340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients
Survey found insurance premiums grew faster than inflation in 2020
Growth in 340B program has not translated to improvements for patients
Cancer medicines cost twice as much at hospitals, study finds
New GAO report: Some hospitals participating in 340B may not be eligible for the program
Nearly 50% of brand medicine spending goes to the supply chain and others
New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018
Hospitals make 9 times more than physicians’ offices on provider-administered medicines
340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients
Study finds hospitals continue to mark up medicines up to 500% of their cost
Fresh data show, yet again, 340B is growing while charity care dwindles at many 340B hospitals
New study finds hospitals continue to push patients to costlier outpatient settings
340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings
New study finds hospitals prescribe more medicines, and more expensive medicines, after joining 340B program
New study finds some hospitals mark up medicine prices at least 700 percent
New analysis finds 340B medicine sales hit record high in 2017 and continue to grow as a share of total drug spending
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
GAO again recommends improvements to 340B program
ICYMI: Analysis finds higher outpatient drug spending at 340B hospitals
New 340B analysis: Hospitals raking in billions while uncompensated care drops by billions
Patients pay the price when hospitals mark up cancer medicines
340B Spotlight: How much money are hospitals pocketing under 340B and what are they doing with those profits?
340B Spotlight: Hospital system adds voice to comments about flawed 340B program
Fact Check Friday: The truth about the cost of 340B to patients
340B Spotlight: New pieces of legislation continue momentum to fix 340B program
340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform
How much are hospitals marking up the price of medicines? The answer may surprise you.
340B Spotlight: New analysis finds 340B program growth continues to accelerate despite false claims
340B Spotlight: ICYMI – AJC looks at how some Georgia hospitals are profiting off 340B
340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients
340B Spotlight: Audit findings show importance of increased oversight of 340B program
Why Congress should prioritize fixing the 340B program
340B
Hospitals
Why Congress should prioritize fixing the 340B program
Why Congress should prioritize fixing the 340B program